. 2026 Jul 13;23(1):31–40. doi: 10.4274/tjps.galenos.2026.80025

Table 2. MBC (mg/L) of synthesized DDSs against gram-negative and gram-positive bacteria.

Synthesized DDSs	P. aeruginosa ATCC 27853	E. coli ATCC 25922	K. pneumoniae ATCC 4352	P. vulgaris ATCC 13315	E. faecalis ATCC 29212	S. epidermidis ATCC 12228	S. aureus ATCC 29213	A. baumannii ATCC 19606	MRSA ATCC 43300
ZIF-8	-	-	-	-	625	39.06	625	-	-
ZIF-8@TA	-	-	-	-	625	78.12	1250	-	-
ZIF-8 @TA @Cu	-	-	-	1250	625	312.5	625	-	-
ZIF-8 @ TA @ CTX	-	-	-	-	625	312.5	1250	-	-
ZIF-8 @TA @Cu@CTX	-	-	-	-	156.25	19.53	1250	-	-
CTX	8	0.6	0.06	16	1	1	2	32	8
Reference	0.5^a	0.06^a	0.5^a	0.125^a	2^a	0.25^a	0.06^a	0.5^a	1^b

^aMeropenem; ^bCiprofloxacin. ATCC, American Type Culture Collection; CTX, cefotaxime; DDSs, drug delivery systems; MBC, minimum bactericidal concentration; MRSA, methicillin-resistant S. aureus; TA, tannic acid; ZIF, zeolitic imidazolate framework; CU, copper ion.